146 related articles for article (PubMed ID: 3491578)
1. Saccade responses to dopamine in human MPTP-induced parkinsonism.
Hotson JR; Langston EB; Langston JW
Ann Neurol; 1986 Oct; 20(4):456-63. PubMed ID: 3491578
[TBL] [Abstract][Full Text] [Related]
2. [Spontaneous saccades in MPTP-induced hemi-parkinsonian monkeys].
Usui S; Fukuda H; Hikosaka O
Rinsho Shinkeigaku; 1990 Nov; 30(11):1181-9. PubMed ID: 2085922
[TBL] [Abstract][Full Text] [Related]
3. Memory-contingent saccades and the substantia nigra postulate for essential blepharospasm.
Hotson JR; Boman DR
Brain; 1991 Feb; 114 ( Pt 1A)():295-307. PubMed ID: 1998888
[TBL] [Abstract][Full Text] [Related]
4. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
[TBL] [Abstract][Full Text] [Related]
5. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
Lange KW
Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
[TBL] [Abstract][Full Text] [Related]
6. MPTP: a pharmacological tool to study parkinsonism.
Kulkarni SK; Mehta AK; Aley KO; Shukla VK
Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):485-9. PubMed ID: 3489146
[TBL] [Abstract][Full Text] [Related]
7. Activity of substantia nigra pars reticulata neurons during smooth pursuit eye movements in monkeys.
Basso MA; Pokorny JJ; Liu P
Eur J Neurosci; 2005 Jul; 22(2):448-64. PubMed ID: 16045498
[TBL] [Abstract][Full Text] [Related]
8. Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates.
Wichmann T; Kliem MA; DeLong MR
Exp Neurol; 2001 Feb; 167(2):410-24. PubMed ID: 11161630
[TBL] [Abstract][Full Text] [Related]
9. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
Frohna PA; Rothblat DS; Joyce JN; Schneider JS
Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343
[TBL] [Abstract][Full Text] [Related]
10. [Mechanism of induction of parkinsonism by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a dopaminergic neurotoxin].
Hirata Y; Nagatsu T
Tanpakushitsu Kakusan Koso; 1986 Apr; 31(5):398-409. PubMed ID: 3520683
[No Abstract] [Full Text] [Related]
11. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
12. Nigral and adrenal grafts in parkinsonism: recent basic and clinical studies.
Olson L; Backlund EO; Gerhardt G; Hoffer B; Lindvall O; Rose G; Seiger A; Strömberg I
Adv Neurol; 1987; 45():85-94. PubMed ID: 3030073
[No Abstract] [Full Text] [Related]
13. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
[TBL] [Abstract][Full Text] [Related]
14. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.
Sagi Y; Mandel S; Amit T; Youdim MB
Neurobiol Dis; 2007 Jan; 25(1):35-44. PubMed ID: 17055733
[TBL] [Abstract][Full Text] [Related]
15. Biochemical mechanisms underlying MPTP-induced and idiopathic parkinsonism. New vistas.
Singer TP; Ramsay RR; Sonsalla PK; Nicklas WJ; Heikkila RE
Adv Neurol; 1993; 60():300-5. PubMed ID: 8380523
[No Abstract] [Full Text] [Related]
16. Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior, histology, and biochemistry.
Schneider JS; Yuwiler A; Markham CH
Exp Neurol; 1986 Feb; 91(2):293-307. PubMed ID: 3484707
[TBL] [Abstract][Full Text] [Related]
17. MPTP toxicity: clinical features.
Williams A
J Neural Transm Suppl; 1986; 20():5-9. PubMed ID: 3489070
[TBL] [Abstract][Full Text] [Related]
18. GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.
Schneider JS; Kean A; DiStefano L
J Neurosci Res; 1995 Sep; 42(1):117-23. PubMed ID: 8531220
[TBL] [Abstract][Full Text] [Related]
19. Metabolic mapping of the oculomotor system in MPTP-induced parkinsonian monkeys.
Ho VW; Porrino LJ; Crane AM; Burns RS; Kopin IJ; Sokoloff L
Ann Neurol; 1988 Jan; 23(1):86-9. PubMed ID: 3257855
[TBL] [Abstract][Full Text] [Related]
20. Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys.
Graybiel AM; Moratalla R; Quinn B; DeLanney LE; Irwin I; Langston JW
Adv Neurol; 1993; 60():34-9. PubMed ID: 8420148
[No Abstract] [Full Text] [Related]
[Next] [New Search]
